Delhaize, Dexia, Omega Pharma, Vastned: Benelux Equity Preview

The following companies may have unusual price changes in Benelux markets. Stock symbols are in parentheses, and prices are from the previous close.

The AEX-Index (AEX) in Amsterdam declined 3.2 percent to 300.85. Belgium’s Bel20 Index sank 2.9 percent to 2,223.67. Luxembourg’s LuxX Index tumbled 3.6 percent to 1,232.67.

Dutch stocks:

Vastned Offices/Industrial NV (VNOI NA): The property fund that plans to merge with Nieuwe Steen Investments NV said its first-half direct investment result fell to 10.1 million euros ($14.3 million) from 13.1 million euros a year earlier. The shares lost 3.4 percent to 9.50 euros.

Vastned Retail NV (VASTN) : The Dutch owner of shopping centers in the Netherlands, Spain, France and Belgium said its first-half direct investment result was unchanged at 33.6 million euros. The shares fell 4.3 percent to 42.90 euros.

Belgian stocks:

Delhaize Group SA (DELB) : The owner of the Food Lion supermarkets in the U.S. may say second-quarter net income rose to 118.8 million euros, according to the average of six analyst estimates compiled by Bloomberg, from 114 million euros a year earlier. Delhaize retreated 0.3 percent to 47.03 euros.

Dexia SA (DEXB) : Belgium’s largest bank by assets reported a record quarterly net loss of 4.03 billion euros, which included a 377 million-euro pretax writedown of Greek debt holdings, and said central-bank funding increased to about 34 billion euros at the end of June. Dexia decreased 1.5 percent to 1.66 euros.

Omega Pharma NV (OME BB): Belgium’s biggest supplier of pharmacy products reported first-half earnings excluding some items rose to 1.45 euros a share from 1.44 euros a year earlier. Earnings missed the 1.52 euro-a-share median estimate of five analysts surveyed by Bloomberg News. Omega Pharma (OME) dropped 2.6 percent to 30.77 euros.

To contact the reporter on this story: John Martens in Brussels at jmartens1@bloomberg.net

To contact the editor responsible for this story: Angela Cullen at acullen8@bloomberg.net

Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.